Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma
Autore:
Menendez, R; Stanford, RH; Edwards, L; Kalberg, C; Rickard, K;
Indirizzi:
Ctr Asthma & Allergy, El Paso, TX 79925 USA Ctr Asthma & Allergy El Paso TX USA 79925 Allergy, El Paso, TX 79925 USA GlaxoSmithKline Inc, Res Triangle Pk, NC USA GlaxoSmithKline Inc Res Triangle Pk NC USA Inc, Res Triangle Pk, NC USA
Titolo Testata:
PHARMACOECONOMICS
fascicolo: 8, volume: 19, anno: 2001,
pagine: 865 - 874
SICI:
1170-7690(2001)19:8<865:CAOFPV>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
INHALED CORTICOSTEROIDS; BUDESONIDE; MORTALITY; CHILDREN; TRENDS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Menendez, R Ctr Asthma & Allergy, 10470 Vista Sol, El Paso, TX 79925 USA Ctr Asthma & Allergy 10470 Vista Sol El Paso TX USA 79925 USA
Citazione:
R. Menendez et al., "Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma", PHARMACOECO, 19(8), 2001, pp. 865-874

Abstract

Objective: To compare the relative value of an inhaled corticosteroid, fluticasone propionate 88 mug twice daily, versus an oral leukotriene receptorantagonist, zafirlukast 20 mg twice daily, in patients with persistent asthma currently receiving short acting beta (2)-agonists alone. Study design: A cost-efficacy analysis using resource utilisation and clinical data obtained prospectively from a multicentre, randomised, double-blind, double-dummy, placebo-controlled 12-week clinical trial conducted in the US. Perspective: Third-party payor. Patients and methods: A total of 451 corticosteroid-naive patients with persistent asthma were treated with either fluticasone propionate 88 mug twice daily or zafirlukast 20 mg twice daily. All patients were given salbutamol (albuterol) to be used as rescue medication. Data were examined using intent-to-treat analysis. Results: Mean daily per person cost-efficacy ratios using improvement in forced expiratory volume in I second (FEV1) [greater than or equal to 12% increase from baseline] were $US3.47 for fluticasone propionate compared with$US7.81 for zafirlukast (1999 values). The mean daily per person cost-efficacy ratios for symptom-free days obtained were $US5.51 for fluticasone propionate compared with $US14.98 for zafirlukast. These cost-efficacy ratios remained in favour of fluticasone propionate after a robust sensitivity analysis. Conclusions: Treatment with fluticasone propionate 88 tg twice daily was the most cost effective treatment compared with zafirlukast 20 mg twice daily in this 12-week clinical trial. This analysis supports the use of fluticasone propionate 88 mug twice daily as first-line treatment in patients withpersistent asthma previously treated with short-acting beta (2)-agonist alone.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/07/20 alle ore 12:45:55